Salute e Benessere
First-Ever Multicenter Study of Hypothermic Oxygenated Perfusion (HOPE) with VitaSmart™ in Pediatric Liver Transplants Confirms Safety and Favorable Outcomes
Conducted across , results demonstrated that HOPE improves graft preservation by reducing reliance on static cold storage (liver preservation on ice alone) and mitigating ischemia-reperfusion injury, a serious complication that can compromise graft function. Importantly, the authors concluded that HOPE is safe in pediatric liver transplantation and is particularly beneficial for grafts with prolonged ischemia, including those from Donation after Circulatory Death (DCD) donors.
"These results highlight the , and its safety in the pediatric population," said , a global leader in transplant solutions and sponsor of the pivotal clinical trial. "By extending preservation time and protecting vulnerable grafts, this technology can increase the number of viable organs available for children awaiting transplantation—helping to reduce waiting times and save more lives."
Bridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as , , and the . With a strong focus on product quality, innovation, and accessibility, the company partners with leading Transplant Centers and Organ Procurement Organizations worldwide.
Logo - https://mma.prnewswire.com/media/2085277/Bridge_to_Life_New_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/first-ever-multicenter-study-of-hypothermic-oxygenated-perfusion-hope-with-vitasmart-in-pediatric-liver-transplants-confirms-safety-and-favorable-outcomes-302558430.html